logo

For the Inventor, By the Inventor

Newark, DE, United States of America

Chao Qi

This inventor holds 17 USPTO granted patents and 14 published patent applications and 3 EPO patents, primarily in Heterocyclic Compounds. Top assignee: Incyte Corporation. Active years: 2020-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Chao Qi. Retrieved from https://idiyas.com/inventor/chao-qi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 17 

% Patents Active = 94.1

 

Average Co-Inventor Count = 7.3

ph-index = 4

Forward Citations = 70(Granted Patents)


Location History:

  • Newark, DE (US) (2020 - 2024)
  • Wilmington, DE (US) (2024)

Company Filing History:

goldMedal17 out of 687 
 
Incyte Corporation
 patents

Years Active: 2020-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
Fused Pyrazine Derivatives
A2A/A2B Inhibitors
Heterocyclic Compounds
Immunomodulators
KRAS Inhibitors
Naphthyridine Compounds
Quinoline Compounds
Bicyclic Heterocycles
FGFR Inhibitors
Imidazole
Triazole
Pyrazolopyrimidine Compounds
17 patents (USPTO):Explore Patents
1. 12735424 - Fused pyrazine derivatives as A2A / A2B inhibitors (2026-09-15),
2. 12466822 - Heterocyclic compounds as immunomodulators (2025-11-11),
3. 12441742 - Naphthyridine compounds as inhibitors of KRAS (2025-10-14),
4. 12441731 - Pyrazolopyrimidine compounds and uses thereof (2025-10-14),
5. 12378243 - Quinoline compounds as inhibitors of KRAS (2025-08-05),
6. 12083124 - Bicyclic heterocycles as FGFR inhibitors (2024-09-10),
7. 12077539 - Imidazole and triazole KRAS inhibitors (2024-09-03),
8. 12060433 - CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy (2024-08-13),
9. 11999740 - Fused pyrazine derivatives as A2A / A2B inhibitors (2024-06-04),
10. 11939328 - Quinoline compounds as inhibitors of KRAS (2024-03-26),
11. 11673894 - Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors (2023-06-13),
12. 11607416 - Bicyclic heterocycles as FGFR inhibitors (2023-03-21),
13. 11591329 - Bicyclic heterocycles as FGFR inhibitors (2023-02-28),
14. 11339149 - Heterocyclic compounds as immunomodulators (2022-05-24),
15. 11161850 - Fused pyrazine derivatives as A2A / A2B inhibitors (2021-11-02),

Title: Chao Qi: Innovator in Pharmaceutical Compounds

Introduction

Chao Qi is a prominent inventor based in Newark, DE (US), known for his significant contributions to the field of pharmaceuticals. With a total of 15 patents to his name, he has made remarkable strides in developing compounds that target critical pathways in cancer treatment.

Latest Patents

Among his latest innovations are two notable patents. The first patent involves naphthyridine compounds that serve as inhibitors of KRAS. These compounds are designed to inhibit KRAS activity and are useful in treating, preventing, or ameliorating diseases associated with KRAS activity, such as cancer. The second patent focuses on pyrazolopyrimidine compounds, which inhibit ALK2 and FGFR activities. These compounds also hold promise in treating diseases related to these pathways, particularly cancer.

Career Highlights

Chao Qi is currently employed at Incyte Corporation, where he continues to advance his research and development efforts. His work has been instrumental in creating innovative solutions for complex medical challenges.

Collaborations

Chao has collaborated with notable colleagues, including Wenqing Yao and Liangxing Wu, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Chao Qi's work exemplifies the impact of innovative thinking in the pharmaceutical industry. His patents not only reflect his expertise but also his commitment to improving cancer treatment options.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…